ArriVent BioPharma/$AVBP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ArriVent BioPharma

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Ticker

$AVBP
Sector
Primary listing

Employees

52

AVBP Metrics

BasicAdvanced
$772M
-
-$4.02
-
-

What the Analysts think about AVBP

Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.

Bulls say / Bears say

Phase 1b FURTHER data showed a 16.0-month median progression-free survival, 53% overall response rate, and 41% confirmed complete response in CNS evaluable EGFR PACC mutant NSCLC patients, supporting the launch of the global pivotal ALPACCA Phase 3 study in the second half of 2025
Completion of a $75 million public offering, backed by joint book-runners Goldman Sachs, Citigroup and Guggenheim, provides critical funding to advance firmonertinib and next-generation ADC programs through key clinical milestones
Coverage initiation by Guggenheim with a buy rating and $45 price target, alongside an average analyst target of $39.40, points to strong institutional confidence in ArriVent’s clinical pipeline upside
Shares down approximately 22% year-to-date reflect investor skepticism around ArriVent’s long clinical timelines and lack of approved products
Announcement of a $75 million equity offering drove a 4.7% post-market share decline, underscoring dilution concerns among shareholders
Analyst sentiment is mixed: only 4 of 8 covering firms rate the stock as buy/strong-buy, with the remainder at hold and a median $40 price target, suggesting limited near-term upside from current levels
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.

AVBP Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AVBP Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AVBP

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy ArriVent BioPharma stock | $AVBP Share Price | Lightyear